Дело C-702/21: Laboratoire Pareva/Комисия и др., Съдебно решение от 10 ноември 2022 г.

Текст

... as an existing active substance for use in biocidal products of product-types 1, 5 and 6 – Approval as an existing active substance for use in biocidal products of product-types 2 and 4 – Teratogenic effect – Human health risk assessment)

In Case C‑702/21 P,

APPEAL under Article 56 of the Statute of the Court of Justice of the European Union, brought on 19 November 2021,

Laboratoire Pareva, established in Saint-Martin-de-Crau (France), represented by S. Englebert, M. Grunchard and M. Ombredane, avocats, P. Sellar, advocaat, and by K. Van Maldegem, avocat,

appellant,

the other parties to the proceedings being:

Biotech3D Ltd & Co. KG, established in Gampern (Austria),

applicant at first instance,

European Commission, represented by R. Lindenthal and K. Mifsud-Bonnici, acting as Agents,

defendant at first instance,

French Republic, represented by G. Bain and J.-L. Carré, acting as Agents,

European Chemicals Agency (ECHA), represented by C. Buchanan, M. Heikkilä and T. Zbihlej, acting as Agents,

interveners at first instance,

THE COURT (Eighth Chamber),

composed of N. Piçarra, acting as President of the Chamber, N. Jääskinen and M. Gavalec (Rapporteur), Judges,

Advocate General: J. Kokott,

Registrar: A. Calot Escobar,

having regard to the written procedure,

having decided, after hearing the Advocate General, to proceed to judgment without an Opinion,

gives the following

Judgment

1. By its appeal, Laboratoire Pareva seeks to have set aside the judgment of the General Court of the European Union of 15 September 2021, Laboratoire Pareva and Biotech3D v Commission (T‑337/18 and T‑347/18, EU:T:2021:594), by which ...